Abstract:Background/Aim: In recent years, the relationship between miR-200 expression and prognosis in lung cancer patients has been studied extensively. The miR-200 family plays a vital role in occurrence, development, metastasis, and drug resistance of lung cancer. Increasing evidence has shown that the miR-200 family is highly expressed in lung cancer and associated with poor prognosis. However, results have been inconclusive. Therefore, the aim of this study was to assess the association between miR-200 family expression and the clinicopathological and prognostic significance in patients with lung cancer via conducting a meta-analysis. Methods: A total of 9 different publications were searched from PubMed, Web of Science, Embase, and Cochrane library databases. Summary hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects/fixed-effects models. Results: A total of nine articles, consisting of 812 patients, were included in this meta-analysis. Pooling all eligible studies, this study found a shorter overall survival in patients with high expression of the miR-200 family (HR = 2.29, 95% CI: 1.10-4.73). Furthermore, subgroup analysis, based on area, demonstrated that a significant association was found between higher expression of the miR-200 family and poor overall survival (HR = 4.70, 95% CI: 1.5913.89) in the European population. However, there was no significant association between high expression of the miR-200 family and poor PFS (HR = 1.40, 95% CI: 0.21-9.25). In addition, this study failed to observe a correlation of increased miR-200 family expression with clinicopathological parameters, including age, sex, histology, tumor node metastasis (TNM) stage, lymph node metastasis, and tumor differentiation. Conclusion: High expression of the miR-200 family is significantly associated with poor clinical outcomes, particularly decreasing overall survival for European populations. Future studies should be performed to confirm the clinical utility of the miR-200 family in lung cancer.

Increased Expression of Microrna-150 is Associated with Poor Prognosis in Non-Small Cell Lung Cancer

Expression of microRNA-150 in Peripheral Blood and Its Clinical Significance in Patients with Non-Small Cell Lung Cancer

MicroRNA-155 Expression Has Prognostic Value in Patients with Non-small Cell Lung Cancer and Digestive System Carcinomas

Up-Regulation Of Microrna-93 Predicates Advanced Clinicopathological Features And Serves As An Unfavorable Risk Factor For Survival Of Patients With Non-Small Cell Lung Cancer

Reduced Mir-105-1 Levels Are Associated with Poor Survival of Patients with Non-Small Cell Lung Cancer.

Prognostic Value of Microrna-10B Overexpression in Peripheral Blood Mononuclear Cells of Nonsmall-Cell Lung Cancer Patients

Microrna Profiling and Prediction of Recurrence/Relapse-Free Survival in Stage I Lung Cancer

Prognostic Implications of Decreased Microrna-101-3p Expression in Patients with Non-Small Cell Lung Cancer

miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer.

Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Down-Regulation of Mir-452 is Associated with Poor Prognosis in the Non-Small-Cell Lung Cancer

Potential Use of Microrna-200C As a Prognostic Marker in Non-Small Cell Lung Cancer.

Prognostic and clinicopathological significance of microRNA-200 family in lung cancer : a meta-analysis

Serum MicroRNA‐150 Predicts Prognosis for Early‐Stage Non‐Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1

Expression and Clinical Significance of Mir-139-5p in Non-Small Cell Lung Cancer

Prognostic Value of Decreased Microrna-133A in Solid Cancers: a Meta-Analysis.

Mir-145 Expression Level in Tissue Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma.

Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer.

Expression of Micrornas-106B in Nonsmall Cell Lung Cancer

Decreased Mirna-148a is Associated with Lymph Node Metastasis and Poor Clinical Outcomes and Functions As A Suppressor of Tumor Metastasis in Non-Small Cell Lung Cancer

A Microrna Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy.